- $627.43m
- $969.53m
- $573.28m
- 61
- 37
- 88
- 67
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.65 | ||
| PEG Ratio (f) | 0.17 | ||
| EPS Growth (f) | 172.71% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.24 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 16.6 | ||
| Price to Sales | 1.09 | ||
| EV to EBITDA | 25.8 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.31% | ||
| Return on Equity | -20.86% | ||
| Operating Margin | -2.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 321.16 | 430.9 | 512.12 | 512.35 | 573.28 | 564.87 | 599.3 | 11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +24.52 | +197.61 | -84.07 | n/a | n/a | +720.84 | +29.38 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Directors
- William Hawkins NEC (67)
- Kenneth Reali CEO (55)
- Gregory Anglum CFO (50)
- Alessandra Pavesio SVP (54)
- Katrina Church SVP (59)
- Anthony D'adamio SVP (60)
- Sharon Klugewicz SVP (53)
- John Nosenzo OTH (63)
- Mary Ladone DRC (55)
- Patrick Beyer IND
- Philip Cowdy IND (53)
- Michelle Mcmurry - Heath IND
- Guido Neels IND (72)
- Guy Nohra IND (60)
- Susan Stalnecker IND (68)
- Martin Sutter IND (66)
- Stavros Vizirgiankis IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 22nd, 2015
- Public Since
- February 11th, 2021
- No. of Shareholders
- 257
- No. of Employees
- 930
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 82,017,547
- Address
- 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM, 27703
- Web
- https://www.bioventus.com/
- Phone
- +1 9194746700
- Auditors
- Grant Thornton LLP
Latest News for BVS
Upcoming Events for BVS
Q1 2025 Bioventus Inc Earnings Release
Bioventus Inc Annual Shareholders Meeting
Bioventus Inc Annual Shareholders Meeting
Q2 2025 Bioventus Inc Earnings Release
Similar to BVS
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
As of Today at 01:35 UTC, shares in Bioventus are trading at $7.65. This share price information is delayed by 15 minutes.
Shares in Bioventus last closed at $7.65 and the price had moved by +87.96% over the past 365 days. In terms of relative price strength the Bioventus share price has outperformed the S&P500 Index by +73.49% over the past year.
The overall consensus recommendation for Bioventus is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBioventus does not currently pay a dividend.
Bioventus does not currently pay a dividend.
Bioventus does not currently pay a dividend.
To buy shares in Bioventus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $7.65, shares in Bioventus had a market capitalisation of $627.43m.
Here are the trading details for Bioventus:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BVS
Based on an overall assessment of its quality, value and momentum Bioventus is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Bioventus is $15.00. That is 96.08% above the last closing price of $7.65.
Analysts covering Bioventus currently have a consensus Earnings Per Share (EPS) forecast of $0.66 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioventus. Over the past six months, its share price has underperformed the S&P500 Index by -38.96%.
As of the last closing price of $7.65, shares in Bioventus were trading -24.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bioventus PE ratio based on its reported earnings over the past 12 months is 10.65. The shares last closed at $7.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bioventus' management team is headed by:
- William Hawkins - NEC
- Kenneth Reali - CEO
- Gregory Anglum - CFO
- Alessandra Pavesio - SVP
- Katrina Church - SVP
- Anthony D'adamio - SVP
- Sharon Klugewicz - SVP
- John Nosenzo - OTH
- Mary Ladone - DRC
- Patrick Beyer - IND
- Philip Cowdy - IND
- Michelle Mcmurry - Heath - IND
- Guido Neels - IND
- Guy Nohra - IND
- Susan Stalnecker - IND
- Martin Sutter - IND
- Stavros Vizirgiankis - IND